Syndax’s Revuforj Wins 2026 Prix Galien USA Award
Revuforj received the Prix Galien USA award for Best Product for Rare/Orphan Diseases. Syndax says it is the first and only menin inhibitor approved for adults and children one year and older.
Revuforj received the Prix Galien USA award for Best Product for Rare/Orphan Diseases. Syndax says it is the first and only menin inhibitor approved for adults and children one year and older.